Quintrio
Home

Stock overview

Novo-Nordisk A/S

NVO

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Last trade $40.70
Day change -$0.90 (-2.16%)
Day range $40.28 – $41.53
Volume 12,213,869
Market cap $183.35B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for NVO.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for NVO.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue

Johnson & Johnson demonstrates strong revenue growth with consistent quarter-over-quarter increases, while Novo Nordisk struggles with largely flat revenue despite a notable spike in Q1 2026. JNJ's diverse portfolio of 28+ billion-dollar products contrasts with Novo Nordisk's challenges as competitors catch up in the GLP-1 weight loss market.

Zacks Investment Research

NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema

Novo Nordisk received European Commission approval for Frehemgo (denecimig), a next-generation bispecific antibody for hemophilia A prophylaxis. The company also presented positive Phase III data for CagriSema, showing 20.7-21.0% weight loss at 68 weeks versus 2.0% for placebo, with FDA decision expected in Q4 2026. However, Novo faces intensifying competition from Eli Lilly's obesity and diabetes drugs.

GlobeNewswire Inc.

Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035

The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.

The Motley Fool

Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027

An analysis of two leading weight-loss drug manufacturers projects that $10,000 invested equally between Eli Lilly and Novo Nordisk could grow to approximately $11,230 by end of 2027. Eli Lilly is experiencing strong momentum with 39% revenue growth and upcoming retatrutide filing, while Novo Nordisk is bouncing back with oral Wegovy success and the promising CagriSema candidate. Both companies are positioned to benefit from the fast-growing obesity treatment market.

The Motley Fool

Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB?

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) and iShares Biotechnology ETF (IBB). PPH focuses on 26 large, established drugmakers with lower volatility, higher dividend yield (1.8%), and lower expense ratio (0.36%). IBB offers broader diversification with 243 holdings but higher volatility and minimal dividend yield (0.2%). The author recommends PPH for long-term investors seeking stability and income, particularly given the major pharmaceutical companies' acquisition activity in biotech.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Aug 17, 2026$0.5792Aug 25, 2026recurring
Mar 30, 2026$1.2174Apr 8, 2026recurring
Aug 18, 2025$0.5843Aug 26, 2025recurring
Mar 31, 2025$1.1426Apr 8, 2025recurring
Aug 16, 2024$0.5169Aug 26, 2024recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 20, 20232-for-1forward split
Jan 9, 20145-for-1forward split
Dec 17, 20072-for-1forward split